Piper Jaffray & Co. initiates coverage on Salix Pharmaceuticals (Nasdaq: SLXP) with an Overweight. Price target $17.

Piper analyst says ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE